Entheon Announces Termination of Business Combination Agreement with Nutravisor

Entheon Biomedical has terminated its definitive business combination agreement with Nutravisor Inc., first announced in December 2025 as a reverse takeover that would have transformed the company into STRYK Brands Inc. The termination came on May 25, 2026. As part of the breakup, Nutravisor will pay Entheon CAD $175,000 in cash and issue common shares with an aggregate deemed value of CAD $175,000 (priced at the greater of $0.50 or 80% of the next liquidity-event price). The previously planned 6.93:1 share consolidation, CSE listing as a new entity, and all related steps are cancelled. Entheon’s shares remain halted from trading.

The termination is a material negative event. The reverse takeover was the sole value proposition for Entheon shareholders over the past six months. It promised a $40 million valuation for the new business, new management led by Nutravisor’s Max Krangle, a potential $4‑10 million equity financing, and a path toward a consumer‑brand operating company. With the collapse of this deal: - Entheon reverts to being a micro‑cap shell with no operating business update in the provided news flow. Its original psychedelic‑medicine focus appears dormant. - The $350,000 total consideration (half in cash, half in illiquid private-company shares) is negligible against the lost transformative upside. - The stock is halted and will almost certainly reprice lower once trading resumes, as the primary catalyst has vanished. - Break‑fee economics: Entheon receives a modest net cash injection but loses the $100,000 mutual break‑fee structure and the $500,000 finder’s‑fee placeholder that would have been paid in shares of the resulting issuer. This is a small positive in the very short term but does not offset the strategic failure. - The value originally allocated to Entheon’s existing shareholders—approximately $1.5 million post‑consolidation—evaporates, leaving only the pre‑deal, sub‑$2 million market cap. Overall, the development is a clear setback, worsening the company’s survival prospects and investor sentiment.

Entheon Biomedical Corp. originally positioned itself in the psychedelic drug‑development space. No recent operational milestones were included in the news flow, and the company effectively suspended its original business plan in favor of the reverse takeover. Following the termination, Entheon is a shell with no active flagship project. The intended consumer‑brand pivot (STRYK Brands) is off the table.